Hem/Onc Roundup: Diabetes Drug Increases Risk of Pancreatic Cancer, FDA Seeks Male Breast Cancer Treatments, and more

Here are the top stories covered by DocWire News this week in the Hematology & Oncology section. This week, a study found that a certain diabetes drug class increases the risk of developing pancreatic cancer, a text messaging intervention may improve colonoscopy adherence, and more.

Patients with type 2 diabetes who are treated with dipeptidyl peptidase-4 inhibitors are at risk for developing pancreatitis and pancreatic cancer, according to a study published in Diabetes Care.

Cancer survivors enrolled in high deductible health plans may delay or forgo cancer follow-up care, according to a study published in Journal of Oncology Practice. “[High deductible health plan] enrollment may serve as a barrier to access to care among cancer survivors,” according to the authors, although they noted that involvement in a health savings account could mitigate this affect.

The combination of ibrutinib (Imbruvica®), lenalidomide (Revlimid®), and rituximab (Rituxan®) had a manageable safety profile and demonstrated durable activity in patients with relapsed/refractory diffuse large B-cell lymphoma, according to a study published in Blood.

A text message reminder one week prior to a scheduled colonoscopy significantly decreased the number of patients who did not show up to their appointment, according to a study published in Health Education & Behavior.

The U.S. Food and Drug Administration issued a draft guidance calling for the inclusion of male patients in clinical trials for breast cancer drugs.

In case you missed it, more hem/onc headlines are featured below: